Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

摘要: Dendritic cells (DC), master antigen-presenting that orchestrate interactions between the adaptive and innate immune arms, are increasingly utilized in cancer immunotherapy. Despite remarkable progress our understanding of DC immunobiology, as well several encouraging clinical applications — such DC-based sipuleucel-T for metastatic castration-resistant prostate clinically effective immunotherapy monotherapy a majority tumors remains distant goal. The complex interplay diverse molecular processes govern resistance to vaccination compels multimodality approach, encompassing growing arsenal antitumor agents which target these distinct synergistically enhance function. These include antibody-based targeted therapies, checkpoint inhibitors, therapies inhibit immunosuppressive cellular elements, conventional cytotoxic modalities, potentiating adjuvants. It is likely emerging era “precision” therapeutics, tangible benefits will only be realized with multifaceted—and personalized—approach combining adjunctive strategies.